2026 Global: Human Liver Models Market-Competitive Review (2032) report
Description
The 2026 Global: Human Liver Models Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Key players in the human liver models market span the Americas, Europe, and Asia, reflecting a rapid expansion of microphysiological systems designed for hepatocyte physiology, drug metabolism, and disease modeling. Emulate, Inc. is headquartered in Boston, United States, and leads the field with the Liver-Chip platform that integrates perfused channels and living liver cells to recapitulate hepatic architecture. CN Bio Innovations operates from Cambridge, United Kingdom, offering liver models for toxicology and pharmacokinetics research. Mimetas, based in Leiden, Netherlands, commercializes OrganoPlate liver models enabling high-throughput co-culture and drug screening. TissUse GmbH, headquartered in Berlin, Germany, develops multi-organ chips that include hepatic modules for systemic pharmacology studies. AxoSim Technologies, located in Charleston, United States, focuses on microphysiological systems for liver and other organ interfaces, with workflow-compatible products for drug testing. These firms exemplify diverse approaches to liver models, from microfluidic chips to integrated organ systems.
Other notable players include InSphero AG, headquartered in Schlieren, Switzerland, which provides 3D cell-based liver models for high-content screening and toxicity testing. Organovo Holdings, Inc., based in San Diego, United States, offers native tissue-like liver constructs via 3D bioprinting for pharmacology and disease research. SynVivo Ltd., headquartered in Cambridge, United Kingdom, develops microfluidic platforms enabling vascularized liver tissue models for drug metabolism studies. Sekisui XenoTech’s XenoTech division operates from Lenexa, United States, delivering primary human hepatocytes, hepatocyte cultures, and liver-related assays for preclinical testing. AIM Biotech Pte. Ltd., headquartered in Singapore, Singapore, provides organ-on-a-chip platforms and ready-to-use liver modules to support academic and industry liver research. Together these firms leverage diverse scales, delivering hepatocyte-informed models for preclinical safety, disease research, personalized medicine. Their portfolios emphasize liver microenvironment control, consistent phenotypes, and scalability that integrates with routine workflows, enabling faster decision-making in pharmaceutical development. Aiming to reduce animal testing and timelines.
Collectively, these ten companies illustrate a market distinguished by modular approaches, cross-disciplinary collaborations, and increasing integration with regulatory science. The geographic spread—from North America to Europe and Asia—reflects a global demand for human-relevant models that can mitigate late-stage failures and reduce reliance on animal data. Innovations in microfluidics, biomaterials, and stem cell–derived hepatocytes are fueling more predictive models of drug metabolism, transporter activity, and cholestasis, while standardization efforts aim to improve reproducibility and data comparability across laboratories. Strategic partnerships among device developers, pharmaceutical companies, and academic groups are accelerating the translation of liver-on-a-chip and related liver models into risk assessment frameworks, and precision medicine. As regulatory agencies gain experience with MPS data, collaborations across academia and industry are likely to shorten development timelines. The liver models market therefore stands at the intersection of biology, engineering, and data science, promising more humane and predictive assays for chemical risk assessment and safety.
Key players in the human liver models market span the Americas, Europe, and Asia, reflecting a rapid expansion of microphysiological systems designed for hepatocyte physiology, drug metabolism, and disease modeling. Emulate, Inc. is headquartered in Boston, United States, and leads the field with the Liver-Chip platform that integrates perfused channels and living liver cells to recapitulate hepatic architecture. CN Bio Innovations operates from Cambridge, United Kingdom, offering liver models for toxicology and pharmacokinetics research. Mimetas, based in Leiden, Netherlands, commercializes OrganoPlate liver models enabling high-throughput co-culture and drug screening. TissUse GmbH, headquartered in Berlin, Germany, develops multi-organ chips that include hepatic modules for systemic pharmacology studies. AxoSim Technologies, located in Charleston, United States, focuses on microphysiological systems for liver and other organ interfaces, with workflow-compatible products for drug testing. These firms exemplify diverse approaches to liver models, from microfluidic chips to integrated organ systems.
Other notable players include InSphero AG, headquartered in Schlieren, Switzerland, which provides 3D cell-based liver models for high-content screening and toxicity testing. Organovo Holdings, Inc., based in San Diego, United States, offers native tissue-like liver constructs via 3D bioprinting for pharmacology and disease research. SynVivo Ltd., headquartered in Cambridge, United Kingdom, develops microfluidic platforms enabling vascularized liver tissue models for drug metabolism studies. Sekisui XenoTech’s XenoTech division operates from Lenexa, United States, delivering primary human hepatocytes, hepatocyte cultures, and liver-related assays for preclinical testing. AIM Biotech Pte. Ltd., headquartered in Singapore, Singapore, provides organ-on-a-chip platforms and ready-to-use liver modules to support academic and industry liver research. Together these firms leverage diverse scales, delivering hepatocyte-informed models for preclinical safety, disease research, personalized medicine. Their portfolios emphasize liver microenvironment control, consistent phenotypes, and scalability that integrates with routine workflows, enabling faster decision-making in pharmaceutical development. Aiming to reduce animal testing and timelines.
Collectively, these ten companies illustrate a market distinguished by modular approaches, cross-disciplinary collaborations, and increasing integration with regulatory science. The geographic spread—from North America to Europe and Asia—reflects a global demand for human-relevant models that can mitigate late-stage failures and reduce reliance on animal data. Innovations in microfluidics, biomaterials, and stem cell–derived hepatocytes are fueling more predictive models of drug metabolism, transporter activity, and cholestasis, while standardization efforts aim to improve reproducibility and data comparability across laboratories. Strategic partnerships among device developers, pharmaceutical companies, and academic groups are accelerating the translation of liver-on-a-chip and related liver models into risk assessment frameworks, and precision medicine. As regulatory agencies gain experience with MPS data, collaborations across academia and industry are likely to shorten development timelines. The liver models market therefore stands at the intersection of biology, engineering, and data science, promising more humane and predictive assays for chemical risk assessment and safety.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
